Despite objections by pharmaceutical companies against price regulations, at least three major companies agreed to such terms in the context of COVID-19 vaccine contracts. Although the COVID-19 constitutes an unexpected situation, these contracts set a precedent for future agreements regarding price controls in the United States.
According to Washington University associate law professor Rachel Sachs, “COVID has changed the conventional wisdom around a number of different kinds of policies in the innovation context for new drugs, devices and vaccines. And I wouldn’t be surprised if this was part of a rethink of drug pricing issues as well.” Learn more here.
(Source: Sarah Karlin-Smith, Pink Sheet, Informa Pharma Intelligence, 2/8/21)